BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin CEO Interview, Healthcare Comments Off on BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

 

 

 

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease), now in Phase III FDA clinical trials.

BrainStorm’s technology is based on using the patients own stem cells, extracted from bone marrow, which are then grown in proprietary conditions, converting them into “biological factories” secreting a variety of neurotrophic factors (NTFs). These stem cells are then re-injected into the patient. NTFs are growth factors known to support the survival of neurons in a variety of conditions, and in animal models of many neurodegenerative diseases. 

Investor Presentation

brainstorm

 

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

July 29, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV VANCOUVER, Washington, Jul 26, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]

Newsmakers

CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

November 20, 2019 admin Newsmakers Comments Off on CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]

Healthcare

FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

June 24, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s (OTC: CYDY) 510(k) Application for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 24, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications today announced that […]